| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ian Frazer | Q930011 |
| Nana H. Overgaard | Q58894109 | ||
| James W Wells | Q89737937 | ||
| Fiona Simpson | Q37374131 | ||
| P2093 | author name string | Ji-Won Jung | |
| Michael T Burke | |||
| Nicole Isbel | |||
| P2860 | cites work | The immune phenotype may relate to cancer development in kidney transplant recipients. | Q47610143 |
| Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. | Q50610813 | ||
| Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod | Q50699088 | ||
| Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. | Q51780136 | ||
| Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. | Q53308204 | ||
| Cyclosporine induces cancer progression by a cell-autonomous mechanism. | Q53426083 | ||
| Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis. | Q54358726 | ||
| In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | Q54383060 | ||
| Sirolimus and secondary skin-cancer prevention in kidney transplantation. | Q55056496 | ||
| Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. | Q55066538 | ||
| Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation | Q56899012 | ||
| Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive | Q24306328 | ||
| Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. | Q43239536 | ||
| Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice | Q43297973 | ||
| Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor | Q43873032 | ||
| Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy | Q44013375 | ||
| Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis | Q44113049 | ||
| Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo | Q44280916 | ||
| Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression | Q44552336 | ||
| In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. | Q44758532 | ||
| Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies | Q44963400 | ||
| Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines | Q45075612 | ||
| Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation. | Q45136999 | ||
| Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells | Q45229049 | ||
| Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells | Q46104296 | ||
| Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus | Q46168057 | ||
| Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines | Q46333985 | ||
| Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer | Q46472074 | ||
| Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. | Q46492984 | ||
| Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus | Q46646689 | ||
| The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. | Q46934214 | ||
| mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
| Azathioprine and UVA light generate mutagenic oxidative DNA damage | Q24657288 | ||
| Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid | Q27733135 | ||
| Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A | Q28216139 | ||
| A mammalian protein targeted by G1-arresting rapamycin-receptor complex | Q28243712 | ||
| Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug | Q28476740 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. | Q33748547 | ||
| Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking | Q33800990 | ||
| Transcriptional control of effector and memory CD8+ T cell differentiation | Q34064074 | ||
| The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism | Q34086959 | ||
| Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells | Q34168242 | ||
| Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients | Q34200966 | ||
| Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation | Q34267100 | ||
| Regulatory T cells in the control of immune pathology. | Q34348983 | ||
| Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency | Q34380652 | ||
| Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens | Q34460068 | ||
| Sirolimus for Kaposi's sarcoma in renal-transplant recipients | Q34556363 | ||
| Azathioprine in dermatology: the past, the present, and the future | Q34557136 | ||
| Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis | Q34580943 | ||
| Opposing roles for calcineurin and ATF3 in squamous skin cancer | Q34632548 | ||
| Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma | Q34717034 | ||
| The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals | Q35191057 | ||
| Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection | Q36298271 | ||
| Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway | Q36334079 | ||
| Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma | Q36357244 | ||
| Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey | Q36381533 | ||
| Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells | Q36453025 | ||
| Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model | Q36501207 | ||
| Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype | Q36610844 | ||
| Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway | Q36648809 | ||
| HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer | Q36659641 | ||
| mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis | Q36745445 | ||
| Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy | Q36908563 | ||
| Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors | Q36959193 | ||
| PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer | Q37025086 | ||
| Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway | Q37067211 | ||
| Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression | Q37236661 | ||
| Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells | Q37317866 | ||
| Cancer incidence and risk factors after solid organ transplantation | Q37483771 | ||
| B cell-specific deficiencies in mTOR limit humoral immune responses. | Q37532105 | ||
| Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma | Q37591675 | ||
| Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies | Q37677129 | ||
| The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism | Q37792556 | ||
| Risk of malignant neoplasms after liver transplantation: a population-based study | Q38454093 | ||
| Cancer incidence before and after kidney transplantation | Q38464934 | ||
| The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling. | Q39297991 | ||
| A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses. | Q39506517 | ||
| Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression | Q39591754 | ||
| Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases | Q39610517 | ||
| CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes | Q39744964 | ||
| Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts | Q39912029 | ||
| Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines | Q40072758 | ||
| Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability | Q40160158 | ||
| Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. | Q41976514 | ||
| Cancer of the head and neck region in solid organ transplant recipients | Q42436651 | ||
| Cutaneous findings in chronic lymphocytic leukaemia | Q42463688 | ||
| Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial | Q42466678 | ||
| Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease | Q42490631 | ||
| Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer | Q42503484 | ||
| Skin tumours in the West of Scotland renal transplant population | Q42515657 | ||
| Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases | Q42517520 | ||
| Chronic diseases requiring hospitalization and risk of non-melanoma skin cancers--a population based study from Denmark | Q42519742 | ||
| Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy | Q42520583 | ||
| Non-melanoma skin cancer risk in the Queensland renal transplant population. | Q42527482 | ||
| The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 | ||
| Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial | Q42610828 | ||
| Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil | Q42673867 | ||
| Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. | Q42790830 | ||
| A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation | Q42921848 | ||
| 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages | Q43088272 | ||
| Mycophenolic acid differentially affects dendritic cell maturation induced by tumor necrosis factor-alpha and lipopolysaccharide through a different modulation of MAPK signaling | Q43119800 | ||
| The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin | Q43199035 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | skin cancer | Q192102 |
| immune function | Q124683452 | ||
| immunosuppression | Q1455316 | ||
| P304 | page(s) | 281-292 | |
| P577 | publication date | 2015-01-22 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? | |
| P478 | volume | 138 |
| Q53812391 | Assessing T-cell abundance in cutaneous squamous cell carcinoma: adding another string to your bow. |
| Q58037249 | Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma |
| Q26799460 | Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients |
| Q91526837 | Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage |
| Q37059878 | Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers |
| Q59356682 | Etiology of increased cancer incidence after solid organ transplantation |
| Q57385046 | Homeostasis, regeneration and tumour formation in the mammalian epidermis |
| Q40949266 | Malignancies of the skin and immunomodulatory antirheumatic therapy |
| Q38684394 | Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. |
| Q64945921 | Primary squamous cell carcinoma of the peristomal skin of gastrostomy in a transplant patient: a first case report. |
| Q64252378 | Protective Antigen Shows High Specificity for a UV Induced Mouse Model of Cutaneous Squamous Cell Carcinoma |
| Q58760715 | Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma |
| Q33873997 | Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients |
| Q64253571 | The Role of the Immune System in Cutaneous Squamous Cell Carcinoma |
| Q46271884 | The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. |
Search more.